497 related articles for article (PubMed ID: 18854691)
1. Medical treatment options for ocular myasthenia gravis.
Antonio-Santos AA; Eggenberger ER
Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
[TBL] [Abstract][Full Text] [Related]
2. Myasthenia gravis: emerging new therapy options.
Sieb JP
Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy choice and maintenance for generalized myasthenia gravis in China.
Zhang C; Bu B; Yang H; Wang L; Liu W; Duan RS; Zhang M; Zeng P; Du C; Yang L; Shi FD
CNS Neurosci Ther; 2020 Dec; 26(12):1241-1254. PubMed ID: 33103369
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis.
Dodd KC; Ahmed R; Ambrose P; Holt JK; Jacob S; Leite MI; Miller JA; San PP; Spillane J; Viegas S; Sussman J
Neuromuscul Disord; 2024 May; 38():51-57. PubMed ID: 38626662
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil in myasthenia gravis: the unanswered question.
Phan C; Sanders DB; Siddiqi ZA
Expert Opin Pharmacother; 2008 Oct; 9(14):2545-51. PubMed ID: 18778192
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil treatment of myasthenia gravis.
Cahoon WD; Kockler DR
Ann Pharmacother; 2006 Feb; 40(2):295-8. PubMed ID: 16403848
[TBL] [Abstract][Full Text] [Related]
8. Ocular myasthenia gravis: an update on diagnosis and treatment.
Fortin E; Cestari DM; Weinberg DH
Curr Opin Ophthalmol; 2018 Nov; 29(6):477-484. PubMed ID: 30281029
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
[TBL] [Abstract][Full Text] [Related]
10. Medical and surgical treatment for ocular myasthenia.
Benatar M; Kaminski H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005081. PubMed ID: 16625623
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil and myasthenia gravis.
Ciafaloni E
Lupus; 2005; 14 Suppl 1():s46-9. PubMed ID: 15803932
[TBL] [Abstract][Full Text] [Related]
12. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
Schneider C; Gold R; Reiners K; Toyka KV
Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
[TBL] [Abstract][Full Text] [Related]
14. Maintenance immunosuppression in myasthenia gravis, an update.
Morren J; Li Y
J Neurol Sci; 2020 Mar; 410():116648. PubMed ID: 31901719
[TBL] [Abstract][Full Text] [Related]
15. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
Lim AK; Donnan G; Chambers B; Ierino FL
Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
[TBL] [Abstract][Full Text] [Related]
17. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Benatar M; Kaminski HJ;
Neurology; 2007 Jun; 68(24):2144-9. PubMed ID: 17460154
[TBL] [Abstract][Full Text] [Related]
18. The muddle of mycophenolate mofetil in myasthenia.
Benatar M; Rowland LP
Neurology; 2008 Aug; 71(6):390-1. PubMed ID: 18678821
[No Abstract] [Full Text] [Related]
19. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.
Cutter G; Xin H; Aban I; Burns TM; Allman PH; Farzaneh-Far R; Duda PW; Kaminski HJ
Muscle Nerve; 2019 Dec; 60(6):707-715. PubMed ID: 31487038
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.
Hauser RA; Malek AR; Rosen R
Neurology; 1998 Sep; 51(3):912-3. PubMed ID: 9748061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
